Health Care [ 8/12 ] | Biotechnology [ 36/76 ]
NASDAQ | Common Stock
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.
Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.
The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo.
It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions.
The company was founded in 2015 and is headquartered in Markham, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 9, 24 | -0.52 Decreased by -420.00% | -0.58 Increased by +10.34% |
| May 10, 24 | -0.58 Decreased by -383.33% | -0.69 Increased by +15.94% |
| Feb 9, 24 | -0.54 Decreased by -315.38% | -1.21 Increased by +55.37% |
| Dec 15, 23 | -0.60 Decreased by -2.90 K% | -0.71 Increased by +15.49% |
| Aug 9, 23 | -0.10 Increased by +72.97% | -0.17 Increased by +41.18% |
| May 11, 23 | -0.12 Increased by +63.64% | -0.17 Increased by +29.41% |
| Feb 10, 23 | -0.13 Increased by +60.61% | -0.19 Increased by +31.58% |
| Dec 16, 22 | -0.02 Increased by +92.59% | -0.39 Increased by +94.87% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.67 M Increased by +15.96% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -1.86 M Increased by +20.26% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by -100.00% | -1.68 M Increased by +26.75% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | -1.12 M Decreased by N/A% | -1.72 M Increased by +38.37% | Increased by +153.86% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.98 M Increased by +65.60% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -2.33 M Increased by +48.91% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 1.12 M Increased by +N/A% | -2.29 M Increased by +47.67% | Decreased by -204.93% Decreased by N/A% |
| Sep 30, 22 | 0.00 Increased by +100.00% | -2.79 M Increased by +24.27% | Decreased by N/A% Decreased by N/A% |